Sarepta Therapeutics (SRPT) Receivables - Net (2010 - 2026)

Sarepta Therapeutics has reported Receivables - Net for 17 years, with the latest figure at $394.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 40.13% year-over-year to $394.8 million; the trailing twelve-month figure through Mar 2026 stood at $394.8 million (down 40.13% YoY), and the FY2025 full-year result was $398.2 million, down 33.85% from the prior year.
• Receivables - Net for Q1 2026 stood at $394.8 million, down from $398.2 million in the prior quarter.
• The five-year high for Receivables - Net was $659.4 million in Q1 2025, with the low at $178.2 million in Q1 2022.
• Average Receivables - Net over 5 years is $360.5 million, with a median of $378.8 million recorded in 2024.
• Year-over-year, Receivables - Net surged 86.52% in 2023 and sank 40.13% in 2026.
• Tracing SRPT's Receivables - Net over 5 years: stood at $214.6 million in 2022, then surged by 86.52% to $400.3 million in 2023, then surged by 50.37% to $602.0 million in 2024, then tumbled by 33.85% to $398.2 million in 2025, then dropped by 0.85% to $394.8 million in 2026.
• The last three Receivables - Net figures came in at $394.8 million (Q1 2026), $398.2 million (Q4 2025), and $395.7 million (Q3 2025), per Business Quant data.

Peer Comparison